www.idosr.org
Niwarinda
©IDOSR PUBLICATIONS
ISSN: 2550-794X
International Digital Organization for Scientific Research
IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(3):37-42, 2025.
https://doi.org/10.59298/IDOSRJSR/2024/10.3.3742
IDOSRJSR10.300000

Smart Nanocarriers and Stimuli-Responsive Systems in Obesity Management

Niwarinda Arnold

Department of Pharmacy Kampala International University Uganda
Email: arnold.niwarinda@studwc.kiu.ac.ug

ABSTRACT

Obesity is a complex, multifactorial disease driven by genetic, metabolic, and behavioral factors. Conventional treatments, including pharmacotherapy and surgery, have limited long-term efficacy and often pose risks. Nanotechnology offers novel strategies for targeted, controlled delivery of anti-obesity agents. Among these, smart nanocarriers and stimuli-responsive systems represent the next generation of therapeutic platforms. These nanocarriers are engineered to release their payloads in response to physiological triggers such as pH, temperature, enzymes, redox gradients, or external stimuli like light and magnetic fields. By improving drug bioavailability, reducing off-target effects, and enabling spatiotemporal control of release, smart nanocarriers significantly enhance therapeutic precision. This review discusses the principles of smart nanocarriers, recent advances in obesity management, translational challenges, clinical perspectives, and future opportunities. Stimuli-responsive systems may transform obesity therapy from conventional, systemic approaches to intelligent, patient-tailored interventions.

Keywords: Smart nanocarriers, Stimuli-responsive systems, Obesity, Controlled drug delivery, Nanomedicine

INTRODUCTION

Obesity has reached epidemic proportions worldwide, affecting more than one billion people according to the World Health Organization[1, 2]. It is characterized by an imbalance between energy intake and expenditure, resulting in excessive fat accumulation and chronic metabolic dysfunction [3]. Obesity increases the risk of type 2 diabetes mellitus, cardiovascular disease, non-alcoholic fatty liver disease, and several cancers, making it one of the leading contributors to global morbidity and mortality[4, 5]. Despite the urgency of the problem, effective and safe long-term treatment options remain limited.

Conventional strategies for managing obesity include lifestyle interventions, pharmacological therapy, and bariatric surgery. Lifestyle modification is considered the first-line approach but often fails due to poor adherence and the complex biological regulation of appetite and satiety[6–8]. Bariatric surgery is effective but invasive, costly, and associated with long-term nutritional complications. Pharmacological therapies, including orlistat, GLP-1 receptor agonists, and sympathomimetics, provide modest weight reduction but face issues of tolerability, side effects, and eventual treatment resistance. Thus, there is a clear need for innovative therapeutic modalities that address obesity more effectively and safely[9, 10].

Nanotechnology provides an exciting frontier in obesity management. Nanocarriers including liposomes, polymeric nanoparticles, dendrimers, micelles, and lipid-based nanoparticles offer several advantages over conventional formulations[11–13]. They improve solubility of poorly water-soluble drugs, protect bioactive compounds from degradation, extend circulation times, and enable targeted delivery to adipose tissue, liver, or the central nervous system. However, conventional nanocarriers still face limitations, particularly with regard to uncontrolled release, off-target distribution, and variability in therapeutic outcomes.

To address these limitations, smart nanocarriers have been developed. These systems are designed to respond to internal or external stimuli, ensuring controlled and targeted release of therapeutic agents[14–16]. Stimuli-responsive systems represent a subset of smart nanocarriers that exploit physiological or pathological triggers to achieve precise spatiotemporal control of drug delivery. Internal stimuli include pH gradients, enzymatic activity, redox states, and hypoxic conditions, while external stimuli involve magnetic fields, ultrasound, light, or temperature[17–20].

For obesity management, stimuli-responsive nanocarriers offer significant advantages. Drugs targeting satiety pathways, adipogenesis, lipolysis, or thermogenesis can be released selectively in adipose tissue, gastrointestinal tract, or hypothalamic neurons. For instance, pH-sensitive nanoparticles can release appetite-regulating peptides in the acidic environment of the stomach or small intestine[21]. Enzyme-responsive systems may

deliver lipase inhibitors directly during fat digestion, reducing systemic exposure. Redox-sensitive carriers can exploit the oxidative stress environment of obese tissues to release anti-inflammatory or metabolic agents[22]. The integration of smart nanocarriers with natural bioactives and gene therapies is particularly promising. Nanoformulations of curcumin, resveratrol, or catechins have already demonstrated improved bioavailability[23]. When combined with stimuli-responsive systems, these compounds can be released in response to obesity-related physiological cues, enhancing efficacy and reducing required doses. Similarly, nucleic acid therapies, including siRNA and miRNA targeting adipogenic genes, can be delivered more safely and precisely using smart nanocarriers.

The potential applications extend beyond therapy to theranostics, where nanocarriers combine therapeutic delivery with diagnostic functions. For example, magnetic nanoparticles can both deliver drugs and monitor adipose tissue responses through imaging. This dual functionality provides opportunities for real-time monitoring of treatment outcomes[24].

Despite their promise, smart nanocarriers face barriers to translation. Biocompatibility, reproducibility, manufacturing scalability, and regulatory hurdles remain significant concerns. Furthermore, the chronic nature of obesity necessitates long-term safety studies, which are still limited for stimuli-responsive systems. This review provides a detailed overview of smart nanocarriers and stimuli-responsive systems in obesity management. Section 2 outlines the principles and types of stimuli-responsive systems. Section 3 highlights recent advances and preclinical applications. Section 4 discusses translational barriers. Section 5 examines clinical perspectives. Section 6 explores future directions, including personalized nanomedicine and integration with digital health technologies.

2. Principles of Smart Nanocarriers and Stimuli-Responsive Systems

Smart nanocarriers represent a major advancement in drug delivery technology due to their unique ability to respond to specific stimuli and release therapeutic agents in a controlled and targeted manner. Their design is based on the strategic use of materials that undergo physicochemical changes such as swelling, degradation, or phase transitions when exposed to certain internal or external cues[25]. This responsiveness enables precise delivery of therapeutic agents directly to the site of action, improving treatment outcomes while reducing systemic side effects. Such a system is particularly valuable in managing chronic metabolic diseases like obesity, where targeted delivery to inflamed adipose tissue or metabolic organs is essential to maximize efficacy and minimize toxicity[25].

Internal stimuli-responsive nanocarriers exploit the distinct microenvironmental differences that exist between healthy and diseased tissues. One of the most widely explored strategies is the development of pH-sensitive nanocarriers, which release their drug payloads in acidic environments[26]. Such conditions are commonly found in the stomach, inflamed adipose tissue, and even within the endosomal or lysosomal compartments of cells, making this approach ideal for delivering drugs selectively to these sites[27]. Enzyme-responsive nanocarriers take advantage of the presence of specific enzymes, such as lipases or proteases, that are overexpressed during certain pathological conditions. These systems degrade in the presence of these enzymes, triggering drug release precisely where it is needed, for instance, during fat digestion or in inflamed tissues[27]. Another important category is redox-responsive nanocarriers, which are designed to utilize disulfide bonds in their structure. These bonds cleave in reductive environments rich in intracellular glutathione, enabling drug release within adipocytes or inflamed tissues that have a higher redox potential. Hypoxia-responsive nanocarriers, on the other hand, are tailored to target low-oxygen microenvironments, which are commonly found in expanding adipose tissue[28]. These carriers release their payload in response to hypoxic conditions, ensuring that drugs reach metabolically active but oxygen-deprived regions, where they are most needed.

In addition to internal triggers, external stimuli-responsive nanocarriers rely on externally applied physical cues to control drug release. Magnetic-responsive nanocarriers are one such example, as they incorporate magnetic nanoparticles that allow drugs to be guided and localized to specific tissues with the help of an external magnetic field. This technique not only enhances precision but also reduces off-target effects[29]. Light-responsive nanocarriers make use of photosensitive molecules that can be activated by specific wavelengths of light, leading to spatially controlled drug release with high precision, which is particularly useful for localized therapy. Ultrasound-responsive nanocarriers utilize acoustic cavitation to disrupt their structure, thereby enabling the controlled release of therapeutic agents at the target site. Temperature-sensitive nanocarriers provide another layer of control by releasing their payloads upon exposure to mild hyperthermia, which can be induced locally to trigger site-specific drug delivery without affecting surrounding healthy tissues[30].

The versatility of stimuli-responsive nanocarriers is further enhanced by combining multiple responsive elements into a single platform, resulting in multi-stimuli-responsive nanocarriers. These systems can integrate dual or even triple triggers to provide more refined control over drug delivery. For example, a nanocarrier that is both pH- and enzyme-sensitive can ensure drug release only within the gastrointestinal tract during fat digestion, thereby maximizing therapeutic action while avoiding premature drug loss in other regions of the body[19, 26, 31]. This level of precision is critical in obesity management, where targeting inflamed adipose tissue or metabolic organs with minimal systemic exposure is key to reducing side effects and improving patient compliance.

Overall, stimuli-responsive nanocarriers represent a powerful and highly adaptable drug delivery platform with significant potential for advancing the treatment of obesity and related metabolic disorders. By responding to specific internal or external cues, these nanocarriers can deliver therapeutic agents with unprecedented precision, thereby minimizing systemic toxicity and maximizing therapeutic benefits. The continued development of single- and multi-stimuli-responsive systems promises to revolutionize obesity therapy, paving the way for safer, more effective, and patient-tailored interventions.

3. Advances in Obesity Management Using Smart Nanocarriers

Recent preclinical studies have demonstrated the potential of smart nanocarriers in targeting obesity-related pathways. pH-sensitive nanoparticles have been used to deliver GLP-1 analogs and PYY peptides, releasing them in the acidic stomach environment to enhance satiety signaling[14, 16]. These systems reduce food intake and improve glucose tolerance in obese animal models. Enzyme-responsive nanocarriers have been designed to release orlistat in the presence of pancreatic lipase, enabling localized inhibition of fat absorption in the gastrointestinal tract. This strategy reduces systemic side effects and improves patient tolerability[15].

Redox-responsive nanoparticles encapsulating curcumin and resveratrol have been tested in obese rodents, releasing their payload in oxidative stress environments within adipose tissue[32]. These formulations reduce inflammation, improve insulin sensitivity, and promote weight loss. Magnetic nanoparticles carrying siRNA targeting adipogenic genes have been directed to adipose depots using external magnetic fields. This localized delivery reduces fat accumulation while minimizing off-target gene silencing[32].

In another innovative approach, light-responsive nanocarriers have been used to control appetite by releasing neuropeptide modulators in hypothalamic regions upon light stimulation, demonstrating the potential of external stimuli in regulating feeding behavior[33]. These advances highlight how smart nanocarriers not only improve drug delivery but also enable innovative therapeutic strategies previously unattainable with conventional systems.

4. Translational Barriers

While smart nanocarriers hold immense promise, their clinical translation faces significant barriers. Safety is a primary concern, as responsive materials may generate toxic byproducts upon degradation or trigger immune reactions. Long-term exposure studies are essential, particularly since obesity treatments require chronic use[34–36].

Manufacturing challenges are considerable. Producing stimuli-responsive nanoparticles with consistent size, stability, and responsiveness at industrial scale is technically demanding. Multi-stimuli carriers add further complexity, raising production costs[37].

Regulatory hurdles remain formidable. Regulatory agencies require comprehensive data on safety, reproducibility, and pharmacokinetics. Since smart nanocarriers often combine therapeutic and diagnostic functions, they fall under hybrid regulatory categories, complicating approval pathways[38–40].

Patient variability presents another barrier. Differences in pH, enzyme expression, or oxidative stress among patients may affect responsiveness, reducing uniformity of outcomes. Personalized designs may be needed, but this increases costs and complicates clinical implementation[41].

Finally, cost-effectiveness is critical. Advanced smart nanocarriers are often expensive to develop and produce. Without demonstrating significant improvements over existing treatments, they may struggle to achieve widespread adoption.

5. Clinical Perspectives

Although still in the experimental phase, smart nanocarriers have clear clinical potential. The success of lipid nanoparticles in mRNA vaccines demonstrates the feasibility of nanotechnology-based delivery in humans, paving the way for obesity applications. Smart nanocarriers could provide oral delivery alternatives for peptide drugs like GLP-1 receptor agonists, which are currently injectable[42]. This would improve adherence and expand access. Enzyme-responsive systems delivering orlistat or similar drugs could minimize gastrointestinal side effects while maintaining efficacy.

Combination therapies represent another promising avenue. Smart nanocarriers could deliver both appetite-suppressing agents and anti-inflammatory compounds in a single formulation, addressing multiple obesity pathways simultaneously[42]. Integration with digital health technologies could further enhance clinical applications. Wearable devices monitoring metabolic parameters could trigger external stimuli (e.g., light or ultrasound) to activate nanocarriers at optimal times, personalizing treatment schedules.

However, clinical adoption requires rigorous validation through randomized controlled trials. Demonstrating long-term safety, patient acceptability, and cost-effectiveness will be essential for regulatory approval and widespread clinical use.

Future Directions

The future of smart nanocarriers in obesity management lies in personalization and integration. Advances in genomics, metabolomics, and microbiome profiling will allow therapies tailored to individual patient profiles. Personalized smart nanocarriers could respond to unique physiological cues for optimal therapeutic outcomes. Multi-functional systems will gain prominence. Nanocarriers combining therapeutic, diagnostic, and monitoring functions, theranostics, will enable real-time tracking of drug delivery and metabolic responses.

Hybrid nanocarriers integrating natural compounds, peptides, and nucleic acids will target multiple pathways, offering comprehensive obesity management. Stimuli-responsive platforms capable of delivering gene-editing tools like CRISPR-Cas9 could revolutionize treatment by permanently correcting obesity-related genetic mutations. Advances in biocompatible materials will improve safety. Biodegradable polymers, lipid hybrids, and green nanomaterials will minimize toxicity and enhance clinical acceptability.

Integration with artificial intelligence (AI) will accelerate design and optimize therapeutic strategies. AI algorithms can predict patient responses, identify optimal nanocarrier compositions, and personalize treatment regimens. If these innovations succeed, smart nanocarriers and stimuli-responsive systems could redefine obesity management, shifting from generalized pharmacotherapy to precise, adaptive, and long-term solutions.

CONCLUSION

Smart nanocarriers and stimuli-responsive systems represent a new frontier in obesity management. By responding to physiological and external cues, these platforms enable controlled, targeted, and efficient delivery of therapeutic agents. Preclinical evidence highlights their potential in regulating appetite, adipogenesis, and metabolism. While challenges in safety, manufacturing, and regulation remain, future innovations in personalization, theranostics, and AI integration hold the promise of transforming obesity care into a precise and intelligent therapeutic field.

REFERENCES

1. Ahmed, B., Konje, J.C.: The epidemiology of obesity in reproduction. Best Pract. Res. Clin. Obstet. Gynaecol. 89, 102342 (2023). https://doi.org/10.1016/j.bpobgyn.2023.102342
2. Ahmed, S.K., Mohammed, R.A.: Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions. Metab. Open. 27, 100375 (2025). https://doi.org/10.1016/j.metop.2025.100375
3. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obes. Med. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
4. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B., Alum, E.U.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Nat. Prod. Commun. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
5. Uti, D.E., Ibiam, U.A., Omang, W.A., Udeozor, P.A., Umoru, G.U., Nwadum, S.K., Bawa, I., Alum, E.U., Mordi, J.C., Okoro, E.O., Obeten, U.N., Onwe, E.N., Zakari, S., Opotu, O.R., Aja, P.M.: Buchholzia coriacea Leaves Attenuated Dyslipidemia and Oxidative Stress in Hyperlipidemic Rats and Its Potential Targets In Silico. Pharm. Fronts. 05, e141–e152 (2023). https://doi.org/10.1055/s-0043-1772607
6. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 56, 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
7. Balan, A.I., Halaţiu, V.B., Scridon, A.: Oxidative Stress, Inflammation, and Mitochondrial Dysfunction: A Link between Obesity and Atrial Fibrillation. Antioxidants. 13, 117 (2024). https://doi.org/10.3390/antiox13010117
8. Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
9. Assmann, T.S., Riezu-Boj, J.I., Milagro, F.I., Martínez, J.A.: Circulating adiposity-related microRNAs as predictors of the response to a low-fat diet in subjects with obesity. J. Cell. Mol. Med. 24, 2956–2967 (2020). https://doi.org/10.1111/jcmm.14920
10. Barber, T.M., Kyrou, I., Randeva, H.S., Weickert, M.O.: Mechanisms of Insulin Resistance at the Crossroad of Obesity with Associated Metabolic Abnormalities and Cognitive Dysfunction. Int. J. Mol. Sci. 22, 546 (2021). https://doi.org/10.3390/ijms22020546
11. Azmi, N.A.N., Elgharbawy, A.A.M.: Advances in Medical Applications: The Quest of Green Nanomaterials. In: Shanker, U., Hussain, C.M., and Rani, M. (eds.) Handbook of Green and Sustainable Nanotechnology: Fundamentals, Developments and Applications. pp. 1889–1909. Springer International Publishing, Cham (2023)
12. Bishoyi, A.K., Nouri, S., Hussen, A., Bayani, A., Khaksari, M.N., Soleimani Samarkhazan, H.: Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clin. Exp. Med. 25, 166 (2025). https://doi.org/10.1007/s10238-025-01686-z
13. Alum, E.U., Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
14. Kapalatiya, H., Madav, Y., Tambe, V.S., Wairkar, S.: Enzyme-responsive smart nanocarriers for targeted chemotherapy: an overview. Drug Deliv. Transl. Res. 12, 1293–1305 (2022). https://doi.org/10.1007/s13346-021-01020-6
15. Karimi, M., Zangabad, P.S., Ghasemi, A., Amiri, M., Bahrami, M., Malekzad, H., Asl, H.G., Mahdieh, Z., Bozorgomid, M., Ghasemi, A., Boyuk, M.R.R.T., Hamblin, M.R.: Temperature-Responsive Smart

Nanocarriers for Delivery Of Therapeutic Agents: Applications and Recent Advances. ACS Appl. Mater. Interfaces. 8, 21107–21133 (2016). https://doi.org/10.1021/acsami.6b00371
16. Liu, X., He, F., Liu, M.: New opportunities of stimulus-responsive smart nanocarriers in cancer therapy. Nano Mater. Sci. (2024). https://doi.org/10.1016/j.nanoms.2024.10.013
17. Ashrafizadeh, M., Delfi, M., Zarrabi, A., Bigham, A., Sharifi, E., Rabiee, N., Paiva-Santos, A.C., Kumar, A.P., Tan, S.C., Hushmandi, K., Ren, J., Zare, E.N., Makvandi, P.: Stimuli-responsive liposomal nanoformulations in cancer therapy: Pre-clinical & clinical approaches. J. Controlled Release. 351, 50–80 (2022). https://doi.org/10.1016/j.jconrel.2022.08.001
18. Das, S.S., Bharadwaj, P., Bilal, M., Barani, M., Rahdar, A., Taboada, P., Bungau, S., Kyzas, G.Z.: Stimuli-Responsive Polymeric Nanocarriers for Drug Delivery, Imaging, and Theragnosis. Polymers. 12, 1397 (2020). https://doi.org/10.3390/polym12061397
19. Hou, J., Xue, Z., Chen, Y., Li, J., Yue, X., Zhang, Y., Gao, J., Hao, Y., Shen, J.: Development of Stimuli-Responsive Polymeric Nanomedicines in Hypoxic Tumors and Their Therapeutic Promise in Oral Cancer. Polymers. 17, 1010 (2025). https://doi.org/10.3390/polym17081010
20. Majumder, J., Minko, T.: Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin. Drug Deliv. 18, 205–227 (2021). https://doi.org/10.1080/17425247.2021.1828339
21. Sayed, U.F.S.M., Moshawih, S., Goh, H.P., Kifli, N., Gupta, G., Singh, S.K., Chellappan, D.K., Dua, K., Hermansyah, A., Ser, H.L., Ming, L.C., Goh, B.H.: Natural products as novel anti-obesity agents: insights into mechanisms of action and potential for therapeutic management. Front. Pharmacol. 14, 1182937 (2023). https://doi.org/10.3389/fphar.2023.1182937
22. Olivares-Vicente, M., Herranz-López, M.: The Interplay Between Oxidative Stress and Lipid Composition in Obesity-Induced Inflammation: Antioxidants as Therapeutic Agents in Metabolic Diseases. Int. J. Mol. Sci. 26, 8544 (2025). https://doi.org/10.3390/ijms26178544
23. Awlqadr, F.H., Majeed, K.R., Altemimi, A.B., Hassan, A.M., Qadir, S.A., Saeed, M.N., Faraj, A.M., Salih, T.H., Abd Al-Manhel, A.J., Najm, M.A.A., Tsakali, E., Van Impe, J.F.M., Abd El-Maksoud, A.A., Abedelmaksoud, T.G.: Nanotechnology-based herbal medicine: Preparation, synthesis, and applications in food and medicine. J. Agric. Food Res. 19, 101661 (2025). https://doi.org/10.1016/j.jafr.2025.101661
24. Rarokar, N., Yadav, S., Saoji, S., Bramhe, P., Agade, R., Gurav, S., Khedekar, P., Subramaniyan, V., Wong, L.S., Kumarasamy, V.: Magnetic nanosystem a tool for targeted delivery and diagnostic application: Current challenges and recent advancement. Int. J. Pharm. X. 7, 100231 (2024). https://doi.org/10.1016/j.ijpx.2024.100231
25. Islam, S., Ahmed, M.M.S., Islam, M.A., Hossain, N., Chowdhury, M.A.: Advances in nanoparticles in targeted drug delivery–A review. Results Surf. Interfaces. 19, 100529 (2025). https://doi.org/10.1016/j.rsurfi.2025.100529
26. Wang, T., Wu, C., Hu, Y., Zhang, Y., Ma, J.: Stimuli-responsive nanocarrier delivery systems for Pt-based antitumor complexes: a review. (2023). https://doi.org/10.1039/D3RA00866E
27. AlSawaftah, N.M., Awad, N.S., Pitt, W.G., Husseini, G.A.: pH-Responsive Nanocarriers in Cancer Therapy. Polymers. 14, 936 (2022). https://doi.org/10.3390/polym14050936
28. Ghassemifar, V., Zahedi, A., Meigoli, M.S.S., Mokhtari, T., Zadeh, S.S.M., Parsafar, M., Zenjanab, M.K., Esfahlan, R.J.: Harnessing nanotechnology to modulate hypoxic tumor microenvironments: Enhanced strategies for oncological innovations. Biomed. Pharmacother. 191, 118543 (2025). https://doi.org/10.1016/j.biopha.2025.118543
29. Srivastava, R.: Stimuli-responsive nanomaterials for the precision delivery of mRNA cancer vaccines. Nano Trends. 11, 100147 (2025). https://doi.org/10.1016/j.nwnano.2025.100147
30. Awad, N.S., Paul, V., AlSawaftah, N.M., ter Haar, G., Allen, T.M., Pitt, W.G., Husseini, G.A.: Ultrasound-Responsive Nanocarriers in Cancer Treatment: A Review. ACS Pharmacol. Transl. Sci. 4, 589–612 (2021). https://doi.org/10.1021/acsptsci.0c00212
31. Wells, C.M., Harris, M., Choi, L., Murali, V.P., Guerra, F.D., Jennings, J.A.: Stimuli-Responsive Drug Release from Smart Polymers. J. Funct. Biomater. 10, 34 (2019). https://doi.org/10.3390/jfb10030034
32. Rodríguez-González, G.L., Vargas-Hernández, L., Reyes-Castro, L.A., Ibáñez, C.A., Bautista, C.J., Lomas-Soria, C., Itani, N., Estrada-Gutierrez, G., Espejel-Nuñez, A., Flores-Pliego, A., Montoya-Estrada, A., Reyes-Muñoz, E., Taylor, P.D., Nathanielsz, P.W., Zambrano, E.: Resveratrol Supplementation in Obese Pregnant Rats Improves Maternal Metabolism and Prevents Increased Placental Oxidative Stress. Antioxidants. 11, 1871 (2022). https://doi.org/10.3390/antiox11101871
33. Almadani, I.F., Almadani, M.F., AlSawaftah, N., Abuwatfa, W.H., Husseini, G.A.: Nanocarriers Responsive to Light—A Review. Micro. 4, 827–844 (2024). https://doi.org/10.3390/micro4040051
34. Alkandahri, M.Y., Pamungkas, B.T., Oktoba, Z., Shafirany, M.Z., Sulastri, L., Arfania, M., Anggraeny, E.N., Pratiwi, A., Astuti, F.D., Indriyani, Dewi, S.Y., Hamidah, S.Z.: Hepatoprotective Effect of Kaempferol: A Review of the Dietary Sources, Bioavailability, Mechanisms of Action, and Safety. Adv. Pharmacol. Pharm. Sci. 2023, 1387665 (2023). https://doi.org/10.1155/2023/1387665

35. Awlqadr, F.H., Altemimi, A.B., Qadir, S.A., Hama Salih, T.A., Alkanan, Z.T., AlKaisy, Q.H., Mohammed, O.A., Hesarinejad, M.A.: Emerging trends in nano-sensors: A new frontier in food safety and quality assurance. Heliyon. 11, e41181 (2025). https://doi.org/10.1016/j.heliyon.2024.e41181
36. Campochiaro, C., Farina, N., De Luca, G., Batani, V., Trignani, G., Vignale, D., Palmisano, A., Matucci-Cerinic, M., Dagna, L.: Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies. Arthritis Res. Ther. 26, 79 (2024). https://doi.org/10.1186/s13075-024-03310-z
37. Khalil, A.K.A., Teow, Y.H., Takriff, M.S., Ahmad, A.L., Atieh, M.A.: Recent developments in stimuli-responsive polymer for emerging applications: A review. Results Eng. 25, 103900 (2025). https://doi.org/10.1016/j.rineng.2024.103900
38. 4dm1n_diversatechnologies: Overcoming regulatory hurdles in clinical translation of nanomedicine, https://www.diversatechnologies.com/overcoming-regulatory-hurdles-in-clinical-translation-of-nanomedicine/, (2025)
39. Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., Vora, L.K.: Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape. Small Weinh. Bergstr. Ger. 21, 2502315 (2025). https://doi.org/10.1002/smll.202502315
40. Haist, M., Stege, H., Grabbe, S., Bros, M.: The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment. Cancers. 13, 210 (2021). https://doi.org/10.3390/cancers13020210
41. Mahmoud, S.H., Kharouba, M., Aboelezz, A., Elshamy, A., Gunn, E.: Pharmacotherapy variability and precision medicine in neurocritical care. Front. Neurol. 16, 1630163 (2025). https://doi.org/10.3389/fneur.2025.1630163
42. Aldosari, B.N., Alfagih, I.M., Almurshedi, A.S.: Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. Pharmaceutics. 13, 206 (2021). https://doi.org/10.3390/pharmaceutics13020206

CITE AS: Niwarinda Arnold (2025). Smart Nanocarriers and Stimuli-Responsive Systems in Obesity Management. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(3):37-42. https://doi.org/10.59298/IDOSRJSR/2024/10.3.3742